I am getting a lot of questions around Progenics Pharmaceuticals (PGNX) this week. The company reported earnings Wednesday. Numbers missed the consensus on the top and bottom lines. Investors/trading programs then oversold the shares down to $4.60 a share at one point in trading Wednesday, before calmer heads came in to boost them back over $5.30 a share to begin trading on Friday (Disclaimer: I added 25% to my core holdings of PGNX at $4.95 a share Wednesday).
